Skip to main content
. 2020 Oct 16;13:100727. doi: 10.1016/j.bonr.2020.100727

Table 1.

Patient characteristics at treatment initiation. Results are Mean ± SD. Control groups are patients that were not treated during the study duration.

Control RAL EFV
Age at treatment initiation (y) 42.4 (14) 42.5 (10) 40.7 (8)
Ethnicity % (n)
 Israeli Jew 33.3 (5) 26.6 (4) 26.6 (4)
 Israeli Arab 0 (0) 13.3 (2) 40 (6)
 Ethiopian Jew 46.6 (7) 26.6 (4) 6.6 (1)
 Former USSR 13.3 (2) 13.3 (2) 6.6 (1)
 Other 6.6 (1) 20 (3) 20 (3)
Smoking (Y/N) 4/8 5/9 5/8
Alcohol (Y/N) 1/10 3/11 3/10
Time from diagnosis to treatment initiation (days) 428 (937) 858 (1331) 1301 (1269)
CD4-treatment initiation (cells/μl) 516 (192) 195 (178) 220 (173)
VL at treatment imitation (copies/ml) 28,000 (32000) 204,000 (333,000) 77,000 (111,000)
BMI at treatment initiation kg/M2 25.3 (4.2) 26 (3.6) 23 (3.2)
Nadir CD4 (cells/μl) 317.3 (156) 194.8 (157) 210.6 (142)
OH-25 vitamin D (ng/dl) 27 (18) 23.2 (14) 22.7 (13)
Albumin-corrected calcium (mmol/L) 2.0 (0.3) 2.2 (0.2) 2.1 (0.3)
Phosphorus (mmol/L) 1 (0.2) 1 (0.3) 1 (0.2)
P1NP (ng/ml) 47 (20) 46 (17) 55 (32)
CTX (pg/ml) 288 (264) 341 (296) 243 (161)